What Is the First-Line Treatment for Chronic Urticaria?
Clinical Context
Chronic urticaria is managed with a first-line strategy aimed at preventing the occurrence of wheals and angioedema through continuous, regular pharmacological treatment — not on-demand use.
Treatment Approach
Evidence supports a modern 2nd generation H1-antihistamine taken on a continuous daily basis as first-line symptomatic treatment. The full protocol — including agent selection, dosing schedule, and escalation pathway — is available via the structured regimen.
Treatment Goals
- Complete symptom control: continuous urticaria activity score (UAS) of 0
- Urticaria Control Test (UCT) score of 16
- Reassessment after 1–2 weeks of treatment
References
DOI: 10.1111/all.70210
- We recommend a 2nd generation H1-antihistamine as first-line treatment for all types of urticaria.
- We recommend the use of a standard-dosed modern 2nd generation H1-antihistamines as the first-line symptomatic treatment for urticaria.
- Nonsedating 2nd generation H1-antihistamines, for example, should be used daily, to prevent the occurrence of wheals and angioedema, rather than on demand.
- The goal of treatment is to treat the disease until it is gone, as efficiently and as safely as possible, aiming at a continuous complete control (consistently UAS = 0/UCT = 16) and a normalization of quality of life.
- For updosing, also the time of onset needs to be considered, for example, for treatment with an antihistamine, further improvement cannot be expected after 1–2 weeks of treatment as receptor saturation is complete after 1 week.
View source ↗